Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

BACKGROUND: VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor-specific immune response. This phase I/II study evaluated the safety, tolerability, and efficacy of VB-111 with and without bevaci...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Brenner, Andrew J, Peters, Katherine B, Vredenburgh, James, Bokstein, Felix, Blumenthal, Deborah T, Yust-Katz, Shlomit, Peretz, Idit, Oberman, Bernice, Freedman, Laurence S, Ellingson, Benjamin M, Cloughesy, Timothy F, Sher, Naamit, Cohen, Yael C, Lowenton-Spier, Noa, Rachmilewitz Minei, Tamar, Yakov, Niva, Mendel, Itzhak, Breitbart, Eyal, Wen, Patrick Y
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229257/
https://ncbi.nlm.nih.gov/pubmed/31844886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz231
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars